Last reviewed · How we verify

DESOXYRIBONUCLEASE

FDA-approved approved Enzyme Quality 5/100

DESOXYRIBONUCLEASE is a drug. It is currently FDA-approved (first approved 1964).

At a glance

Generic nameDESOXYRIBONUCLEASE
ModalityEnzyme
PhaseFDA-approved
First approval1964

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DESOXYRIBONUCLEASE

What is DESOXYRIBONUCLEASE?

DESOXYRIBONUCLEASE is a Enzyme drug.

When was DESOXYRIBONUCLEASE approved?

DESOXYRIBONUCLEASE was first approved on 1964.

What development phase is DESOXYRIBONUCLEASE in?

DESOXYRIBONUCLEASE is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing